12:00 AM
 | 
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OC144-093: Phase I

In 18 healthy volunteers, OC144-093 was well tolerated at doses of 200, 300 or 400 mg given at 6, 12...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >